Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System
Published: April 26, 2021
- Hormone-dependent cancers, such as breast and prostate cancer, are the most common non-cutaneous cancers afflicting women and men respectively in the US and worldwide; and together are the second leading individual cause of cancer deaths. As patients with hormone-dependent cancers continue to live longer, cardiovascular disease (CVD) has emerged as a leading cause of mortality and morbidity in this group.
- Baseline CVD and CV risk factors as well as the length of time on therapy increase the risk of CV events associated with hormonal therapies.
- A multi-disciplinary approach to patient care and patient involvement at treatment initiation and follow up is key to simultaneously optimize patients’ oncologic and CV outcomes.
- Commentary: Hormonal Based Therapies in the Treatment of Breast and Prostate Cancer – balancing the risks! by Susan Dent, MD (1), Heather Moore, PharmD (2), and Gretchen Kimmick, MD, MS (3)
- Top Things to Know: Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System
- Commentary: Hormonal Therapy for Breast and Prostate Cancer: Lessons and Opportunities by Jeanne M. DeCara, MD
- News Release: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones
- 2019 Cardio-Oncology: Vascular and Metabolic Perspectives
- 2019 Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors
- 2018 Cardiovascular Disease and Breast Cancer: Where These Entities Intersect
- 2013 Secondary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults